Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
NeuroVoices: James Rowley, MD, on SLEEP 2024 and the Direction of the AASM
June 5th 2024The pulmonologist at Rush Health and immediate past president of the American Academy of Sleep Medicine provided perspective on some of the intriguing changes to sleep medicine and where the field is headed in the coming years.
Doxepin Demonstrates Effectiveness to Treat Sleep Latency in Insomnia
June 4th 2024Assessing doses of 3 mg doxepin, results revealed non-statistically significant improvements in latency to sleep onset and latency to persistent sleep that were observed across patients above and at or below the median baseline values.
Adverse Events of Low-Sodium Oxybate in Idiopathic Hypersomnia Begin Early in Treatment Course
June 3rd 2024Regardless of whether patients were treatment-naïve or taking alerting agents, the safety profile of low-sodium oxybate remained true, with treatment-emergent adverse events attributing to less than 4% of study discontinuations.
Perspectives on Enable and Serina's New Partnership to Develop SER-252 for Parkinson Disease
May 30th 2024Mike Hooven, chairman and CEO of Enable Injections, and Randall Moreadith, MD, PhD, chief development officer of Serina Therapeutics, provided insight on the development plans of SER-252, an investigational apomorphine therapy for advanced Parkinson disease.
MAGNIFY-MS Analysis Further Demonstrates Cladribine’s Direct Impact on Central Nervous System in MS
May 29th 2024Over a 24-month treatment period, patients on cladribine demonstrated no axonal loss evident on OCT, with reductions in cerebrospinal fluid neurofilament light and impacts on oligoclonal bands.
Pregnancy and Infant Outcomes Remain Unchanged With Multiple Sclerosis Therapy Ocrelizumab
Published: May 29th 2024 | Updated: May 29th 2024Overall, the results mirrored previous reports demonstrating that patients on ocrelizumab before or during pregnancy did not have elevated risk of adverse pregnancy and infant outcomes.
Safety Concerns Arise Amid Andexanet’s Superior Performance in Hematoma Expansion Resolution
May 27th 2024Overall, a significantly greater amount of patients on Andexanet had hematoma volume expansion of 35% or less; however, these patients had greater risk of thrombolytic events and lower modified Rankin scale scores at 30 days.